Cambia Health Solutions, a series A investor, was joined in a $10m series B round of funding by two additional strategic investors: California’s Heritage Provider Network, and Mitsui & Co. (USA) to back GNS Healthcare.
GNS Healthcare uses patented big data analytics methods to build predictive models and products to discover the underlying causal relationships in healthcare and predict the effects of health interventions for individual patients. These models and products are used by pharmaceutical companies, health plans, and providers to address a number of crucial population health management questions, including predicting individual and population risk and costs, comparing the effectiveness of treatments, targeting member engagement to improve medication adherence, and discovering biomarkers that predict patient response to medications.
“Personalizing health care means putting the consumer at the center of all we do, and this requires us to approach opportunities in a new way,” said Mark Ganz, president and CEO of Cambia Health Solutions and chairman of the trade organization America’s Health Insurance Plans. “Supporting transformative businesses like GNS Healthcare benefits our health plan members and brings a new value proposition based on data analytics to the entire US healthcare industry.”
“It is clear that data-driven healthcare is the future of the industry, from finding optimal combinations for cancer therapies to identifying biomarkers for clinical trials. The market potential for big data is huge, as it will radically change how we develop, pay for, and utilize therapies and other interventions for patients,” said Masahiro Moriyasu, SVP at Mitsui USA. “We are at a critical moment in healthcare, and now is the time to invest in the type of data-driven solutions GNS offers the healthcare industry.”